Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pacira Pharmaceuticals ( (PCRX) ) has provided an announcement.
On January 27, 2026, Pacira BioSciences expanded its Board of Directors from nine to 10 members and appointed veteran biopharmaceutical executive Samit Hirawat, M.D., as a Class III director and member of the Science and Technology Committee, with the appointment announced publicly on January 28, 2026. The addition of Hirawat, an independent director with more than 25 years of clinical development and leadership experience at Bristol Myers Squibb and Novartis, underscores Pacira’s efforts to strengthen its governance and scientific oversight as it seeks to accelerate growth of its non-opioid pain portfolio and advance its pipeline, including next-generation gene therapies, potentially bolstering its competitive position in the non-opioid pain management market.
The most recent analyst rating on (PCRX) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.
Spark’s Take on PCRX Stock
According to Spark, TipRanks’ AI Analyst, PCRX is a Neutral.
The score is supported primarily by solid financial health (very low leverage and strong cash flow conversion) and a generally positive earnings update (improving margins and narrowed revenue guidance). These strengths are offset by weak technicals (price well below key moving averages with bearish momentum) and a relatively expensive valuation (high P/E with no dividend yield support).
To see Spark’s full report on PCRX stock, click here.
More about Pacira Pharmaceuticals
Pacira BioSciences is a biopharmaceutical company focused on innovative non-opioid pain therapies, with a commercial portfolio that includes EXPAREL, a long-acting local analgesic for postsurgical pain; ZILRETTA, an extended-release intra-articular injection for osteoarthritis knee pain; and iovera°, a handheld device delivering drug-free, cryogenic nerve blockade. The company is also developing a pipeline of clinical-stage assets for musculoskeletal pain, led by PCRX-201, a locally administered gene therapy in Phase 2 trials for osteoarthritis of the knee, targeting the growing market for alternatives to opioid-based pain management.
Average Trading Volume: 897,650
Technical Sentiment Signal: Sell
Current Market Cap: $881.9M
For a thorough assessment of PCRX stock, go to TipRanks’ Stock Analysis page.